MedTrace Logo

Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer

NCT07504484 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-03-31

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety, efficacy, and methodological feasibility of sequential administration of neoantigen-based personalized immunotherapy following completion of standard adjuvant therapy in patients with colorectal cancer or non-small cell lung cancer who have undergone radical resection.

Based on previous safety clinical trial results of personalized anti-tumor neoantigen injections, the 300 μg/peptide dose is well tolerated.

Therefore, this study will assess the safety and preliminary efficacy of personalized anti-tumor neoantigen injections at a dose of 300 μg/peptide as consolidation therapy after standard postoperative adjuvant treatment in patients with stage III resectable colorectal cancer or non-small cell lung cancer, aiming to provide novel personalized therapeutic strategies to improve disease-free survival (DFS) and overall survival (OS) in these patients.

Conditions

  • CRC (Colorectal Cancer)
  • Non Small Lung Cancer

Interventions

BIOLOGICAL

iNeo-Vac-P01

iNeo-Vac-P01 employs neoantigen peptides to activate the body's immune system, thereby eliminating residual tumor cells after surgery and preventing tumor recurrence and metastasis, enabling patients to derive greater benefit from personalized immunotherapy. For iNeo-Vac-P01, an innovative personalized immunotherapy based on neoantigens, the administration regimen is as follows: Personalized anti-tumor neoantigen injection (300 μg/peptide) plus GM-CSF (40 μg per injection site) will be administered via subcutaneous injection at multiple sites (around the upper arms and abdomen). Five priming immunizations will be given on Days 1, 4, 8, 15 ± 3, and 22 ± 3. Booster immunizations will be administered on Days 52 ± 7 and 82 ± 7. Additional booster doses may be given at 2-month intervals based on the subject's clinical benefit.

Sponsors & Collaborators

  • Hangzhou Neoantigen Therapeutics Co., Ltd.

    collaborator INDUSTRY

  • Ying Yuan, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07504484 on ClinicalTrials.gov